6949-23-1Relevant articles and documents
TGF-beta receptor inhibitor
-
Paragraph 0142-0144; 0151-0152, (2021/04/28)
The invention provides a compound shown as a formula (I) and a pharmaceutical composition thereof. The compound shown as the formula (I) of the present invention is useful as a TGF-beta receptor inhibitor, particularly a TGF beta RI inhibitor, for example, in the prevention or treatment of various TGF beta RI (ALK5) mediated related diseases.
REACTION OF ORGANIC AZIDES WITH UNSATURATED COMPOUNDS XI. REARRANGEMENTS OF BICYCLIC TRIAZOLINES, OBTAINED FROM TAUTOMERIC 2,4,4-TRIMETHYL-AND 3,3,5-TRIMETHYL-1-METHOXYCYCLOPENTENES AND 4-METHYL-3-NITROBENZENESULFONYL AZIDE
Semenov, V. P.,Ogloblin, K. A.
, p. 711 - 715 (2007/10/02)
The reaction of 4-methyl-3-nitrobenzenesulfonyl azide with the tautomeric 2,4,4-trimethyl- and 3,3,5-trimethyl-1-methoxycyclopentenes leads to the formation of the products from transformation of both triazolines in almost equal ratios.The less substituted triazoline is converted through the corresponding aziridine into the allylsulfonamide, while the more substituted triazoline rearranges preferentially to methyl N-arylsulfonyl-1,3,3-trimethylcyclobutanecarboximidate.